The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis.
about
Pain management for rheumatoid arthritis and cardiovascular or renal comorbidityCardiovascular disease risk scores in the current practice: which to use in rheumatoid arthritis?Association of rheumatoid arthritis susceptibility gene with lipid profiles in patients with rheumatoid arthritisInflammation modulation and cardiovascular disease prevention.Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data.Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease.The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank.The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data.A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registriesExplaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity.Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.Prevalence, incidence and characteristics of the metabolic syndrome (MetS) in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs: the complex relationship between MetS andDevelopment and initial validation of a self-assessed lupus organ damage instrumentNo increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease.Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease.Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach.Obesity and carotid atherosclerosis in African black and Caucasian women with established rheumatoid arthritis: a cross-sectional study.Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis.Assessing incremental value of biomarkers with multi-phase nested case-control studies.Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.Suboptimal cardiovascular risk factor identification and management in patients with rheumatoid arthritis: a cohort analysis.Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis.Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.Development of reduced kidney function in rheumatoid arthritis.Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial.Pitfalls and opportunities in measuring patient outcomes in lupus.Obesity in rheumatoid arthritis.Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review.Cardiovascular disease risk in rheumatoid arthritis: progress, debate, and opportunity.Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.Cardiovascular safety of biologic therapies for the treatment of RA.Managing cardiovascular risk in patients with chronic inflammatory diseases.Examining the risk of cardiovascular disease in patients with psoriasis: a critical review.Cardiovascular risk and the use of biologic agents in rheumatoid arthritis.Glucocorticoid safety for treating rheumatoid arthritis.Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.Prevalence of comorbidities in Mexican mestizo patients with rheumatoid arthritis.
P2860
Q24235971-F8DCECED-D7AC-4C61-B92A-395CE987F228Q28082992-B414A482-6A31-4985-88A1-43861B14D203Q28386085-DB5079A4-B391-4DBE-BA96-323D286F83CEQ30361151-448AA04E-169E-4986-84D9-A5F0AEC72E78Q31005025-05D8D49E-CBF0-46AC-A144-3A48E65ECDD1Q31043666-035C7E53-8E82-470A-901E-E237BE12B170Q33452656-AE8D4235-7E71-4C16-A6A6-F432229DC1EBQ33892790-5E7A0A77-008E-48D8-9713-BB49278564F4Q34109394-E2DEBE49-11D9-4F5B-8C84-554C0D77AA46Q34216770-5B4E8052-0728-4799-89C3-629BE7010145Q34238357-1D3AEE51-0D64-4B40-A209-08E2DADBBD1FQ34986307-7DF21A29-B2AB-496D-943B-9409C0A1AD71Q35135831-FDF151F1-8760-468C-BB8B-0192F5A888E1Q35185494-84FDF360-2B53-4ED2-9F86-74B558D5068CQ35229755-30F85EF0-E4C6-422B-BBF7-053477328F50Q35243557-60A95FBB-B88B-43DC-A7FB-AC259EE81A51Q35377706-30CA72A6-7EB4-469B-B90B-8295E2874DEAQ35754240-DDAA5A91-4CC9-4229-A0AD-FA056B75BED1Q36245756-CD308E48-2AD1-4BD0-8867-299E307E082AQ36702061-A5257850-A5E4-4733-87CF-E519BCE56A35Q36761375-468C3C17-0B1D-4CD0-BC0C-99F3D6C49962Q36901936-37226B10-26D6-4438-926E-04F2466A029DQ36907729-8B717155-B75E-4F43-845B-C2103DE8B5A7Q37307297-FEC2080F-4DDC-44CA-938E-7187FE6A8AD1Q37422931-6DBEDB60-BA48-4B79-9EFB-CBB53C628713Q37620219-63F2FFC1-587C-4DDE-8047-517C40471CF3Q37704498-F556DBD7-D740-4C99-B804-D4969CFECD20Q37738685-34518299-0B7A-43EF-8967-1316CB217119Q37801496-76B4FA77-B7C3-4408-9FB2-7EB2D22BEAAFQ37808889-48DAF269-FAEB-4CAC-8CB8-0F4160518476Q37859676-7C39864D-8210-4E3E-B188-CD12A911481CQ37883018-8142085B-D55D-4C5A-A524-704953D70679Q37956137-E55FBB5C-0026-4495-AEDE-64D909D80252Q37975943-E824CCC0-DE66-41FD-9351-F6A0EC236EF8Q38098647-84270524-0E22-442B-8E82-0AA481012AC8Q38260198-F8BF8FB7-3F36-41CD-AB5B-93DD78922BE7Q38388487-D01C3931-77E5-4427-A9AE-30F2C5D41375Q38401848-ECF55F71-625F-4BBE-B61E-2735C35CB02CQ38561490-A1148A15-93BE-4A4A-99D0-DFB3D16FD7CBQ38691780-E4B1865C-D402-41B3-8E40-B6DB87FD5233
P2860
The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
The risk of myocardial infarct ...... nested case-control analysis.
@en
type
label
The risk of myocardial infarct ...... nested case-control analysis.
@en
prefLabel
The risk of myocardial infarct ...... nested case-control analysis.
@en
P2860
P356
P1476
The risk of myocardial infarct ...... nested case-control analysis.
@en
P2093
Kaleb Michaud
P2860
P304
P356
10.1002/ART.23811
P577
2008-09-01T00:00:00Z